文献速递冠心病心力衰竭与心肌病

苏格兰全国研究:肾衰竭患者心肌梗死与卒中的发病率、治疗及结局趋势

Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study.
PubMed 文献 · Eur Heart J · 2024-01-01

该回顾性全国数据链接研究纳入1996至2016年苏格兰16 050例接受肾脏替代治疗的肾衰竭患者,分析心肌梗死和卒中的年龄标准化发病率、治疗及心血管死亡趋势。结果显示两种事件年龄标准化发病率在男女中均下降约一半,但仍为一般人群的4–8倍(心梗)和2–4倍(卒中);循证心脏保护治疗使用增加,心梗后1年心血管死亡预测概率在男女中均从约76%降至约39%,卒中后亦下降。

要点

  • 肾衰竭患者心梗和卒中年龄标准化发病率20年间在男女中均下降约一半。
  • 肾衰竭患者心梗发病率仍为一般人群的4–8倍,卒中为2–4倍。
  • 心梗后1年心血管死亡预测概率男女均从约76%降至约39%,卒中后亦下降。

核心结论

  • 过去20年肾衰竭患者心肌梗死和卒中发病率减半,但仍显著高于一般人群。
  • 尽管治疗和结局改善,肾衰竭患者心梗和卒中后预后仍然较差。

研究设计与样本

  • 回顾性全国数据链接研究,纳入1996年1月至2016年12月苏格兰所有接受肾脏替代治疗的肾衰竭患者。
  • 共纳入16 050例肾衰竭患者,平均年龄52岁(SD 15),女性占41.5%。
  • 链接全国住院、处方和死亡记录,主要结局为心肌梗死和卒中发病率及后续心血管死亡。
  • 采用广义相加模型估计年龄标准化、性别分层的发病率及心血管和全因死亡趋势。

主要发现

  • 1996至2016年间共发生1992例 incident 心肌梗死(平均年龄66岁,SD 12;女性34.8%)和996例 incident 卒中(平均年龄65岁,SD 13;女性45.1%)。
  • 男性心梗年龄标准化发病率从每10万4376(95%CI 3998–4785)降至1835(95%CI 1692–1988)。
  • 女性心梗年龄标准化发病率从每10万3268(95%CI 2982–3593)降至1369(95%CI 1257–1491)。
  • 男性卒中年龄标准化发病率从每10万1978(95%CI 1795–2175)降至799(95%CI 729–875)。
  • 女性卒中年龄标准化发病率从每10万2234(95%CI 2031–2468)降至903(95%CI 824–990)。

关键数值与推荐

  • 与一般人群相比,肾衰竭患者心肌梗死发病率高4–8倍,卒中发病率高2–4倍。
  • 研究期间循证心脏保护治疗使用增加。
  • 66岁肾衰竭患者心梗后1年心血管死亡预测概率:男性从76.6%降至38.6%,女性从76.8%降至38.8%。
  • 卒中后1年心血管死亡预测概率:男性从63.5%降至41.4%,女性从67.6%降至45.8%。

临床怎么用

  • 肾衰竭患者虽心梗和卒中发病率下降,但仍应视为心血管高风险人群加强管理。
  • 循证心脏保护治疗使用增加与心梗和卒中后心血管死亡预测概率下降相关。
  • 肾衰竭患者发生心梗或卒中后预后仍差,需关注后续心血管死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with kidney failure have a higher risk of cardiovascular disease compared with the general population. Whilst temporal trends of myocardial infarction and stroke are declining in the general population, these have not been evaluated in patients with kidney failure. This study aimed to describe national trends in the incidence, treatment, and outcomes of myocardial infarction and stroke in patients with kidney failure (i.e. on dialysis or with a kidney transplant) over a 20-year period, stratified by age and sex. METHODS: In this retrospective national data linkage study, all patients with kidney failure in Scotland (UK) receiving kidney replacement therapy between January 1996 and December 2016 were linked to national hospitalization, prescribing, and death records. The primary outcomes were the incidence of myocardial infarction and stroke, and subsequent cardiovascular death. Generalized additive models were constructed to estimate age-standardized, sex-stratified incidence rates and trends in cardiovascular and all-cause death. RESULTS: Amongst 16 050 patients with kidney failure [52 (SD 15) years; 41.5% women], there were 1992 [66 (SD 12) years; 34.8% women] and 996 [65 (SD 13) years; 45.1% women] incident myocardial infarctions and strokes, respectively, between January 1996 and December 2016. During this period, the age-standardized incidence of myocardial infarction per 100 000 decreased in men {from 4376 [95% confidence interval (CI) 3998-4785] to 1835 (95% CI 1692-1988)} and women [from 3268 (95% CI 2982-3593) to 1369 (95% CI 1257-1491)]. Similarly, the age-standardized incidence of stroke per 100 000 also decreased in men [from 1978 (95% CI 1795-2175) to 799 (95% CI 729-875)] and women [from 2234 (95% CI 2031-2468) to 903 (95% CI 824-990)]. Compared with the general population, the incidence of myocardial infarction was four- to eight-fold higher in patients with kidney failure, whilst for stroke it was two- to four-fold higher. The use of evidence-based cardioprotective treatment increased over the study period, and the predicted probability of cardiovascular death within 1 year of myocardial infarction for a 66-year-old patient with kidney failure (mean age of the cohort) fell in men (76.6% to 38.6%) and women (76.8% to 38.8%), and also decreased in both sexes following stroke (men, from 63.5% to 41.4%; women, from 67.6% to 45.8%). CONCLUSIONS: The incidence of myocardial infarction and stroke has halved in patients with kidney failure over the past 20 years but remains significantly higher than in the general population. Despite improvements in treatment and outcomes, the prognosis of these patients following myocardial infarction and stroke remains poor.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Gallacher, Yeung, Bell, et al. Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study. Eur Heart J. 2024. PMID: 38426727. doi:10.1093/eurheartj/ehae080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。